Beyond 1 year, the humanized monoclonal antibody mepolizumab maintained real-world efficacy and safety in patients with severe eosinophilic asthma in the REALITI-A cohort study, reports an expert at ERS 2021.
Adding cyclophosphamide to glucocorticoid treatment in patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) was associated with a numerically increased risk of mortality, according to results of the phase III EXAFIP trial.
What used to be a place that holds a perception of relative safety and minimal health risk to its occupants, the office now appears to be a place that is inching its way towards the other side of the respiratory health spectrum, with office-related occupational asthma on the rise, according to findings from a UK cross-sectional study presented at ERS 2021.
Treatment with MV130, a sublingual bacterial immunotherapy, reduces the number of exacerbations in patients with chronic obstructive pulmonary disease (COPD), according to a recent study presented at ERS 2021.
Infants born to mothers who were inactive during pregnancy were more likely to have low lung function compared with those whose mothers were active while pregnant, according to the PreventADALL study presented at ERS 2021.
The administration of inhaled budesonide for the treatment of early COVID-19 in adults reduced the probability of needing urgent medical care and time to recovery, according to findings from the STOIC* trial presented at ERS 2021.
The use of colistimethate sodium (CMS), delivered via the I-neb, reduces pulmonary exacerbations among patients with bronchiectasis and chronic Pseudomonas aeruginosa (P. aeruginosa) infection, according to the PROMIS-1* study presented at ERS 2021.